MARKET

CPHI

CPHI

China Pharma
AMEX

Real-time Quotes | Nasdaq Last Sale

0.2500
+0.0020
+0.81%
After Hours: 0.2400 -0.01 -4.00% 17:01 05/24 EDT
OPEN
0.2531
PREV CLOSE
0.2480
HIGH
0.2800
LOW
0.2360
VOLUME
187.57K
TURNOVER
0
52 WEEK HIGH
1.120
52 WEEK LOW
0.2000
MARKET CAP
12.07M
P/E (TTM)
-3.1847
1D
5D
1M
3M
1Y
5Y
China Pharma GAAP EPS of -$0.07, revenue of $9.6M
China Pharma press release (NYSE:CPHI): FY GAAP EPS of -$0.07. Revenue of $9.6M (-11.7% Y/Y).
Seekingalpha · 03/31 13:38
BRIEF-China Pharma Holdings Reports 2021 Results
reuters.com · 03/31 12:25
China Pharma Holdings, Inc. Reports Fiscal Year 2021 Financial Results
China Pharma Holdings, Inc. (NYSE American: CPHI) ("China Pharma," the "Company" or "We"), an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, today announced financial results for the fiscal yea...
PR Newswire · 03/31 12:00
China Pharma Holding Q3 EPS $(0.02), Same YoY, Sales $2.00M Down From $2.40M YoY
China Pharma Holding (AMEX:CPHI) reported quarterly losses of $(0.02) per share. This is unchanged from the same period last year. The company reported $2.00 million in sales this quarter. This is a 16.70 percent
Benzinga · 11/12/2021 21:49
China Pharma reports Q3 results
China Pharma (NYSE:CPHI): Q3 GAAP EPS of -$0.02. Revenue of $1.98M (-17.5% Y/Y) Press Release
Seekingalpha · 11/12/2021 21:40
BRIEF-China Pharma Holdings, Inc. Reports Third Quarter 2021 Financial Results
reuters.com · 11/12/2021 21:31
BRIEF-China Pharma Holdings, Inc. Reports Second Quarter 2021 Financial Results
reuters.com · 08/13/2021 20:33
China Pharma Holding Q2 EPS $(0.02), Sales $2.40M Down From $3.77M YoY
China Pharma Holding (AMEX:CPHI) reported quarterly losses of $(0.02) per share. The company reported $2.40 million in sales this quarter. This is a 36.36 percent decrease over sales of $3.77 million the same period
Benzinga · 08/13/2021 20:32
More
No Data
Learn about the latest financial forecast of CPHI. Analyze the recent business situations of China Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
No Data
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.06%
Pharmaceuticals & Medical Research
+0.25%
Key Executives
Chairman/President/Chief Executive Officer/Chief Financial Officer/Director
Zhilin Li
Director
Heung Tsui
Independent Director
Gene Bennett
Independent Director
Baowen Dong
Independent Director
Yingwen Zhang
No Data
No Data
About CPHI
China Pharma Holdings, Inc. is a holding company. The Company conducts its production, marketing, finance, development and administrative activities through its subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd. (Helpson) in the People's Republic of China (PRC). It is engaged in the development, manufacture and marketing of pharmaceutical products for human use in connection with various diseases and medical conditions in the PRC. It manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, oral solutions and granules. Its pharmaceutical products are sold on a prescription basis and are approved by the China Food and Drug Administration (the CFDA). The Company manufactured over 20 pharmaceutical products for various diseases and medical indications. It offers products for Central Nervous System (CNS) and Cerebral-Cardiovascular Diseases, Anti-infection and Respiratory Diseases, Digestive Diseases and Others.

Webull offers kinds of China Pharma Holdings, Inc. stock information, including AMEX:CPHI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CPHI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CPHI stock methods without spending real money on the virtual paper trading platform.